Serum Institute, Novavax ink pact for producing over 2 billion vaccine doses

"Today's agreement with Serum Institute enhances Novavax' commitment to equitable global delivery of our COVID-19 vaccine. With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on three continents," said Stanley C. Erck, President and Chief Executive Officer of Novavax. "We continue to work with extraordinary urgency to develop our vaccine, now in Phase 2 clinical trials, and for which we anticipate starting Phase 3 efficacy trials around the world in the coming weeks."

The agreement with SIIPL augments a global supply chain that will deliver over two billion doses of NVX-CoV2373 annually as of 2021.

The antigen component of NVX-CoV2373 is being manufactured at Novavax CZ in Bohumil, Czech Republic (formerly Praha Vaccines), as well as at the following partnered manufacturing sites:

• Biofabri in Spain
• FUJIFILM Diosynth Biotechnologies (FDB) in both North Carolina and Texas in the United States
• FDB in the United Kingdom
• SIIPL in
• SK Bioscience in the Republic of Korea
• Takeda Pharmaceutical Company Limited in Japan

Novavax' Matrix-M adjuvant is now being manufactured at Novavax AB in Uppsala, Sweden and the following partnered manufacturing sites:

• AGC Biologics in the United States and Denmark
• PolyPeptide Group will manufacture two key intermediaries used in Matrix-M in the United States and Sweden

"Signing of the manufacturing agreement with Novavax for NVX-CoV2373 is another great milestone for both companies, which will further strengthen our existing relationship. SIIPL expertise to scale-up and manufacture NVX-CoV2373 will help ensure the supply of this most-needed vaccine," said Adar Poonawalla, Chief Executive Officer of Serum Institute of India.

Read also: COVID-19 Vaccine: Novavax initiates Phase IIb trial in South Africa